Psoriasis is an immune-mediated condition that can produce itchy, painful or scaly skin patches. The extent, location and effect on daily life help guide treatment.
Psoriasis is an immune-mediated condition that can produce itchy, painful or scaly skin patches. The extent, location and effect on daily life help guide treatment. Plaque psoriasis has several treatment options, and an oral medication is not the right starting plan for every person. Joint symptoms need their own assessment.
Topical medicines treat selected affected areas; phototherapy and systemic treatments may be considered for more extensive or difficult disease. Icotyde is an FDA-approved oral IL-23 receptor antagonist, icotrokinra. It is a prescribed tablet rather than an injectable biologic or an unregulated research peptide.
Icotyde is indicated for moderate to severe plaque psoriasis in adults and children age 12 or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. A dermatology assessment distinguishes psoriasis from another rash and considers sites, symptoms and previous treatment. Its US indication does not include psoriatic arthritis.
Document affected areas, discomfort, skin changes and prior treatments. Choose topical, light or systemic care according to the diagnosis and goals. If Icotyde is appropriate, review infection and vaccination precautions and arrange a reliable prescription and follow-up route. Its label uses a once-daily 200 mg tablet on an empty stomach upon waking, with at least 30 minutes before food.
Bring photos, prior dermatology records, treatments tried and a medicine list. Mention recurrent infections, tuberculosis exposure, vaccinations, kidney disease and pregnancy or breastfeeding. The label says to consider TB evaluation based on clinical judgment and complete age-appropriate vaccines. For swallowing difficulty, use the product’s authorized dispersion instructions through the treating team rather than crushing the tablet.
Report signs of infection or a serious allergic reaction. Avoid live vaccines during Icotyde treatment. A widespread severe rash with systemic illness needs urgent assessment. Painful swollen joints or prolonged morning stiffness may indicate psoriatic arthritis and need referral; improvement in plaques should not delay a joint evaluation.
Review skin severity, itch, difficult sites and quality of life as well as adverse effects. Trials measure improvement at planned time points; they do not promise immediate or complete clearance for every person. Reassess if symptoms persist or treatment is difficult to take. For eGFR below 60, the label advises monitoring for potential adverse reactions; discuss any additional kidney assessment with the clinician.
Confirm the clinician’s dermatology pathway and pharmacy access. A sample does not establish refill coverage or long-term suitability. Discuss authorization, costs, monitoring and continuity before starting. Ask your prescribed pharmacy about supply and refill timing.
Nao Medical Mineola: 135 Mineola Blvd, Mineola, NY 11501. Call +19173103371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
The Mineola clinic is at 135 Mineola Blvd, Mineola, NY 11501. Call the selected clinic to confirm today’s hours, the exact service and the appointment. An address does not prove onsite medication, testing or procedure availability.
A consultation starts with the clinical review and required records. Treatment or a procedure depends on suitability, the actual order, safety checks, staff, supplies and any authorization; booking does not guarantee a dose or procedure that day. Document affected areas, discomfort, skin changes and prior treatments. Choose topical, light or systemic care according to the diagnosis and goals. If Icotyde is appropriate, review infection and vaccination precautions and arrange a reliable prescription and follow-up route. Its label uses a once-daily 200 mg tablet on an empty stomach upon waking, with at least 30 minutes before food.
Bring photos, prior dermatology records, treatments tried and a medicine list. Mention recurrent infections, tuberculosis exposure, vaccinations, kidney disease and pregnancy or breastfeeding. The label says to consider TB evaluation based on clinical judgment and complete age-appropriate vaccines. For swallowing difficulty, use the product’s authorized dispersion instructions through the treating team rather than crushing the tablet.
Icotyde is indicated for moderate to severe plaque psoriasis in adults and children age 12 or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. A dermatology assessment distinguishes psoriasis from another rash and considers sites, symptoms and previous treatment. Its US indication does not include psoriatic arthritis.
Icotyde is icotrokinra, an FDA-approved oral IL-23 receptor antagonist for qualifying plaque psoriasis. It is taken as a tablet under specific fasting instructions, rather than as an injectable biologic. It is not a research-use peptide product. Use the prescribed regulated product and review its age, weight, infection and vaccination requirements.
Icotyde’s US indication is moderate-to-severe plaque psoriasis in adults and children age 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. It does not have a reviewed US psoriatic-arthritis indication. New joint swelling, stiffness or pain needs assessment and may need a different treatment plan.
Improvement varies, and the Icotyde plaque-psoriasis studies assessed key skin responses at 16 weeks. That study time point is not a promise of complete clearance or a reason to change the dose yourself. Agree on a review interval and track skin involvement, itch, difficult sites and adverse effects; persistent symptoms may change the plan.
A sample does not remove the need to confirm diagnosis, suitability, safety and affordable continuation. Ask the prescriber how refills will be obtained if authorization remains pending or is denied. Do not assume a sample proves insurance approval or that treatment can continue without interruption.
If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact Sharad Suri at service@naomedical.com or by phone at (917) 633-1548 Extension 288. In our goal to answer your questions as quick as possible, we use the assistance of a large language model wherever applicable. If there are any errors or concerns, please bring it to our attention by emailing us.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
Choose urgent care for a non-emergency illness or minor injury. For preventive visits and ongoing management, explore primary care at this location.
Visiting later? Review after-hours options and confirm clinic hours before traveling. For a life-threatening emergency, call 911.
(917) 310-3371
Facebook
Instagram
Twitter
LinkedIn
